Twelve questions every international patient should ask a Seoul stem cell clinic

I write this checklist as Daniel Park, a Korean-American editor based between Austin and Orange County, who has spent several years coordinating regenerative-medicine consultations for US and EU patients flying into Seoul. The pattern I keep seeing is that international patients arrive with a list of clinic names and book based on Instagram polish or hotel-concierge recommendations whose financial relationships are not disclosed. The Korean Ministry of Food and Drug Safety (MFDS) regulates exosome IV, PRP, and growth-factor mesotherapy at a meaningful level, and the Korea Health Industry Development Institute (KHIDI) maintains a public foreign-patient facilitator registry under Ministry of Health and Welfare authority — but neither substitutes for the diligence a prudent international patient should perform before paying a Seoul clinic. The twelve questions below are the ones I would ask if I were the patient: physician licensure, written aftercare, MFDS-cleared bio-active sourcing, KHIDI registration, English-language coordination depth, and the US-Korea regulatory contrast that determines what a US patient can and cannot do for follow-up once they have flown home. This is editorial orientation; specific clinical decisions belong with a licensed Korean physician.

Question 1 — Is the treating physician personally licensed by the Korean Ministry of Health and Welfare, and can you see the licence number?

The first question is the most basic and the one international patients most often skip because it feels presumptuous. It is not. Korean MOHW physician licences are public information, and the licence number — typically a four-to-six-digit identifier — should appear either on the clinic's regulatory disclosure page, on the consultation paperwork, or be readily provided on request. The reason this matters for a stem cell, exosome, or growth-factor protocol is that the regenerative category in Korea is, in regulatory practice, a physician-administered category — bio-active sourcing, dilution, injection technique, microneedling depth, IV protocol pacing are all clinical decisions that belong to a licensed physician, not to a nurse, an aesthetician, or a coordinator. The international patient who books a Seoul exosome IV without confirming that the treating clinician is a Korean MOHW-licensed physician is making a category error. Ask. Get the number. Note it. If the clinic deflects, that is your answer to whether to book.

Question 2 — Is the clinic registered as a foreign-patient facility under KHIDI?

The Korea Health Industry Development Institute (KHIDI), under Ministry of Health and Welfare authority, operates the foreign-patient attraction facility registry — a public framework that distinguishes clinics with formal infrastructure for international patients (English-language consent, multilingual aftercare, complaint-handling channels, foreign-patient liability frameworks) from clinics without it. The registration number follows the format A-YYYY-MM-DD-NNNNN. The registry is searchable at the KHIDI English portal. International patients should verify the registration before booking, not after. The clinic that has thought through international-patient coordination at the regulatory level is the clinic more likely to manage the trip — visa documentation, airport meet-and-greet, return-flight aftercare, remote photo review — at a level a US, EU, or other international patient is going to actually need. The clinic without KHIDI registration may be a fine clinic for Korean patients and a poor fit for an international one.

Question 3 — Are the exosome, PRP, or growth-factor products MFDS-cleared, and which manufacturer?

The Korean Ministry of Food and Drug Safety (MFDS) regulates exosome products, platelet-rich plasma kits, growth-factor mesotherapy ampoules, and other regenerative bio-actives at the product level. Ask the clinic to disclose the manufacturer and MFDS clearance status of every bio-active in the protocol. Major Korean exosome platforms (the ones with peer-reviewed publication and MFDS clearance) are identifiable, sourceable, and the responsible clinic will name them. The clinic that will not name the manufacturer is sourcing from a route that does not bear scrutiny, and the international patient should walk. This is not a hypothetical risk: MFDS issued public warnings in recent years about unauthorised regenerative product sourcing, and the dividing line between a properly run Seoul exosome practice and an improperly run one is, more than any other single factor, the sourcing chain for the bio-active itself.

Question 4 — Is consent documented in your working language and provided in writing?

Informed consent for a regenerative protocol in Korea must be documented, must be in writing, and for international patients the working language must be one the patient genuinely reads. English-language consent for US, UK, Australian, and most EU patients; Japanese for Japanese patients; simplified or traditional Chinese for Mainland or Taiwanese patients; Spanish for patients from Spain, Mexico, and Latin America; the working language is the patient's primary, not the clinic's convenience. The consent document should describe the protocol, the bio-active product, the expected response window, the side-effect profile, the aftercare regimen, the cost, and the complaint-handling channel. A two-paragraph English summary stapled to a four-page Korean consent is not informed consent in the way an international patient should accept. Ask for the full document in your working language. Read it. Ask questions. Sign only after.

Question 5 — Is there a written aftercare protocol I take home in my working language?

Aftercare is where Seoul regenerative practice most often fails the international patient. The diagnostic question is whether the clinic provides a written aftercare protocol — printed or PDF, in the patient's working language — that the patient takes home. The protocol should cover the first 24 hours, days one through three, four through seven, seven through fourteen, the flight home, and the post-trip window. It should address skincare reintroduction, sun exposure, exercise, alcohol, sleep, hydration, and the remote review schedule. The clinic that has built this document has thought through the international-patient recovery window; the clinic that hands you verbal instructions in halting English on the way out of the procedure room has not. Ask to see the document before booking. If it does not exist, you are agreeing to an aftercare experience the clinic has not built for you.

Question 6 — What is the English-language coordinator's actual role, and are they medically trained?

The English-language coordinator at a Seoul clinic varies enormously in role and qualification. At the better end, the coordinator is a registered nurse with multi-year international-patient experience, handling consent translation, history intake, aftercare documentation, and remote photo review through the post-procedure window. At the lower end, the coordinator is an inbound marketing employee whose primary function is to close the booking. The diagnostic question is what the coordinator's clinical role is during consultation, the procedure day, and the aftercare window. Ask. The clinic running the nurse model will say so clearly; the sales model will be vaguer. Both can produce acceptable outcomes for routine protocols; the divergence appears when something needs clinical judgement during aftercare, which the international patient does not want to discover at hour 36 from a Houston hotel room.

Question 7 — How are emergencies and adverse events handled, and what is the documented chain?

Adverse events from MFDS-cleared exosome IV, PRP, and growth-factor mesotherapy protocols are uncommon and typically minor — extended redness, transient swelling, occasional infection at injection sites — but the responsible Seoul clinic has a documented chain for handling them and the international patient should confirm it before booking. The chain should cover: 24-hour clinical contact channel during the recovery window (WhatsApp, LINE, WeChat, or local phone); on-call physician responsibility; the Seoul hospital partnership for inpatient referral if needed; the international-patient liability insurance the clinic carries (KHIDI-registered facilities maintain mandatory foreign-patient liability coverage); the procedure for handling adverse events that present after the patient has flown home. The clinic that cannot answer these questions clearly has not thought through the responsibility chain; the clinic that can has built the framework the international patient hopes never to use.

Question 8 — What is the post-trip remote review schedule, and how long does it run?

The single most underused element of Seoul regenerative practice is the post-trip remote review channel — typically WhatsApp, LINE, or WeChat — through which the treating physician (or the coordinating nurse acting on the physician's instruction) reviews patient photos at day seven, day fourteen, day twenty-eight, and sometimes day sixty post-procedure. The international patient who flies back to Texas or California on day three or day five is at the start of their response window, not the end of it, and the clinic that runs the remote review at a substantive clinical level is the clinic that catches an issue early when intervention is straightforward rather than late when it is not. Ask the clinic what the remote review schedule looks like, how long it runs, and what specifically is reviewed at each touchpoint. The good answers are detailed; the poor answers are not.

Question 9 — Are pricing, what is included, and what is not included disclosed in writing before payment?

Seoul regenerative pricing varies considerably by district and clinic positioning, and the pattern that produces the most international-patient complaint volume is the gap between the headline number quoted at consultation and the total at checkout. Ask, in writing, for the pricing breakdown: the procedure cost itself, the bio-active product cost (sometimes itemised separately for premium exosome platforms), the consultation fee (sometimes waived if booked, sometimes not), the aftercare product package, any consumable add-ons (numbing cream, post-care masks, supplementary IV ingredients), VAT treatment for international patients (Korea offers VAT-refund eligibility on qualifying medical procedures for foreign patients — confirm whether the clinic processes the refund), and the cost of any follow-up touch-ups discussed at consultation. The good clinic provides this in one document, before payment. The clinic that produces it piecemeal at checkout is producing it that way for a reason.

Question 10 — How does Korean MFDS regulation differ from US FDA regulation, and why does it matter for follow-up?

This is the question most US patients do not know to ask, and the most important one for the period after the flight home. The Korean MFDS regulates exosome products and PRP kits at a level the US FDA does not currently apply uniformly: Korean clinics use MFDS-cleared regenerative bio-actives through licensed-physician administration in a framework without a direct US analogue. When a US patient flies home, the same bio-active product is not legally available through most US dermatology practices, and the patient who imagined a 'follow-up exosome session' to maintain Seoul response will discover the regulatory mismatch at the wrong moment. Ask the Seoul clinic to explain the contrast at consultation, in writing. Plan follow-up as remote photo review with the Seoul clinic — supplemented by US-side conventional dermatology — rather than as a Seoul-protocol-followed-by-home-touch-up framework that the regulatory environment does not support.

Question 11 — How does the clinic handle Google, Kakao, and Naver reviews, and is the review profile authentic?

Korean clinics maintain review presences across Naver, KakaoMap, and Google — each with different collection dynamics and manipulation vulnerabilities. The diagnostic exercise before booking is to read Naver and KakaoMap reviews (Google Translate if needed) alongside the English-language Google reviews. Patterns to watch: an English Google profile uniformly five-star with thin content, paired with a Naver profile that is mixed or thin; review content that reads as marketing rather than patient experience; volume that spiked recently rather than accumulated organically; or an English-language profile that does not exist for a clinic claiming international-patient depth. The clinic with authentic reviews across Korean and international platforms has earned it; the clinic with a curated English profile and a thin Korean one is presenting a different reality to international patients than to Korean ones.

Question 12 — Is the clinic willing to be vetted, and what is the cancellation framework?

The final question is process rather than substance: is the clinic willing to be vetted by an international patient doing diligence properly? The clinic that responds to the eleven questions above with detailed written answers in the patient's working language is signalling that international-patient coordination depth is real. The clinic that deflects, treats the questions as adversarial, or responds with marketing copy is signalling the opposite. Combine this with the cancellation framework: deposit structure (refundable, partial, non-refundable), procedure-day cancellation policy, and rescheduling policy if travel timing changes. The clinic with clear cancellation frameworks has thought through the international-patient experience at the operational level. Ask. Read. Decide. The diligence work you do before booking is what makes the trip a clinical programme rather than a gamble.

Frequently asked questions

How do I verify a Korean physician's licence number?

Request the licence number from the clinic in writing, then verify against Korean Ministry of Health and Welfare records. The number is public information and the clinic should provide it without resistance. Decline to book with any clinic that deflects.

What is KHIDI registration and why does it matter?

KHIDI (Korea Health Industry Development Institute) operates the foreign-patient attraction facility registry under Ministry of Health and Welfare authority. Registration signals formal international-patient infrastructure — multilingual consent, mandatory liability insurance, complaint-handling channels. The registry is publicly searchable.

How can I check whether an exosome product is MFDS-cleared?

Ask the clinic to disclose the manufacturer and clearance status in writing. The MFDS maintains public databases for cleared regenerative products. The clinic unwilling to name the manufacturer is sourcing through a route the international patient should not accept.

Should informed consent be in my native language?

Yes — the full consent document, not just a summary, should be in your working language. A two-paragraph English abstract appended to a four-page Korean document is not informed consent in the way an international patient should accept. Ask for the full English (or your-language) version before signing.

Is a written aftercare protocol standard practice?

At KHIDI-registered facilities serving international patients, written aftercare in the patient's working language is standard. The clinic without this document has not built for the international-patient recovery window, regardless of how polished the consultation experience appears.

How do I evaluate the English-language coordinator's qualifications?

Ask what their clinical role is during the consultation, the day of the procedure, and the aftercare window. The coordinator-as-registered-nurse model produces measurably better aftercare outcomes than the coordinator-as-sales model. Both exist; ask which one you are getting.

What is the difference between Korean MFDS and US FDA regulation of exosomes?

Korean MFDS regulates exosome products and PRP kits at a level the US FDA does not currently apply uniformly. US patients planning Houston, Los Angeles, or New York follow-up touch-ups for a Seoul-administered protocol will encounter regulatory mismatch. Plan remote photo review with the Seoul clinic instead.

How long should remote review with the Seoul clinic continue after I fly home?

Substantive remote review should run at minimum to day twenty-eight, ideally to day sixty, with photo-documented touchpoints at day seven, day fourteen, day twenty-eight, and day sixty. The clinic that runs the remote review at this depth is the clinic that catches issues early.